New study explores how CF drugs change sinus bacteria and smell

NCT ID NCT05982795

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study looks at how CFTR modulator therapy affects the nose and sinuses in adults with cystic fibrosis. Researchers will compare bacterial communities, inflammation, sense of smell, and quality of life between patients on the therapy and those not on it. Participants provide nasal samples, take smell tests, and fill out surveys. The goal is to understand how this therapy impacts chronic sinus problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CFTR modulator therapy
What this could lead to
If successful, this study could reveal how CFTR modulators improve sinus health and quality of life in cystic fibrosis, guiding better management of chronic sinus disease.
What could go wrong
This is a small observational study (30 participants) comparing two groups, not a controlled trial. Results may not apply to all CF patients, and no new treatment is being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dartmouth-Hitchcock Medical Center

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.